%PDF-1.4
%
65 0 obj
<>
endobj
62 0 obj
<>
endobj
128 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T12:04:10Z
2024-03-28T17:42:12-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T17:42:12-07:00
application/pdf
Heather
2002-191.april
uuid:11373968-1dd2-11b2-0a00-3c09278d5b00
uuid:1137396b-1dd2-11b2-0a00-1e0000000000
endstream
endobj
51 0 obj
<>
endobj
52 0 obj
<>
endobj
66 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
158 0 obj
[162 0 R]
endobj
159 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(6.)-875.1 (Stefanovic-Racic M, Meyers K, Meschter C, Cof)17.7 (fey JW)91.7 (, Hof)17.7 (fman)]TJ
1.675 -1.25 Td
[(RA, Evans CH. N-monomethyl ar)17.7 (ginine, an inhibitor of nitric oxide)]TJ
0 -1.25 TD
(synthase, suppresses the development of adjuvant arthritis in rats.)Tj
T*
(Arthritis Rheum 1994;37:1062-9.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Cannon GW)91.7 (, Openshaw SJ, Hibbs JB Jr)39.7 (, Hoidal JR, Huecksteadt)]TJ
1.675 -1.25 Td
[(TP)110.7 (, Grif)17.7 (fiths MM. Nitric oxide production during adjuvant-induced)]TJ
T*
[(and collagen-induced arthritis. )54.8 (Arthritis Rheum 1996;39:1677-84.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Connor JR, Manning PT)73.9 (, Settle SL, et al. Suppression of )]TJ
1.675 -1.25 Td
(adjuvant-induced arthritis by selective inhibition of inducible nitric)Tj
T*
(oxide synthase. Eur J Pharmacol 1995;273:15-24.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Stefanovic-Racic M, Meyers K, Meschter C, Cof)17.7 (fey JW)91.7 (, Hof)17.7 (fman)]TJ
1.675 -1.25 Td
(RA, Evans CH. Comparison of the nitric oxide synthase inhibitors)Tj
T*
[(methylar)17.7 (ginine and aminoguanidine as prophylactic and therapeutic)]TJ
T*
(agents in rat adjuvant arthritis. J Rheumatol 1995;22:1922-8.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (McCartney-Francis NL, Song X, Mizel DE, )17.7 (W)79.9 (ahl SM. Selective)]TJ
2.175 -1.25 Td
(inhibition of inducible nitric oxide synthase exacerbates erosive)Tj
T*
(joint disease. J Immunol 2001;166:2734-40.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (V)110.8 (eihelmann )54.8 (A, Landes J, Hofbauer )54.8 (A, et al. Exacerbation of)]TJ
2.1381 -1.25 Td
(antigen-induced arthritis in inducible nitric oxide synthase-deficient)Tj
T*
[(mice. )54.8 (Arthritis Rheum 2001;44:1420-7.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Farrell )54.8 (AJ, Blake DR, Palmer RM, Moncada S. Increased )]TJ
2.175 -1.25 Td
(concentrations of nitrite in synovial fluid and serum samples)Tj
T*
[(suggest increased nitric oxide synthesis in rheumatic diseases. )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 1992;51:1219-22.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Stichtenoth DO, Fauler J, Zeidler H, Frolich JC. Urinary nitrate)]TJ
2.175 -1.25 Td
(excretion is increased in patients with rheumatoid arthritis and)Tj
T*
[(reduced by prednisolone. )54.8 (Ann Rheum Dis 1995;54:820-4.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Ueki )36.8 (Y)128.9 (, Miyake S, )17.7 (T)69.9 (ominaga )36.8 (Y)128.9 (, Eguchi K. Increased nitric oxide)]TJ
2.175 -1.25 Td
(levels in patients with rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(1996;23:230-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Di Rosa M, Radomski M, Carnuccio R, Moncada S.)]TJ
2.175 -1.25 Td
(Glucocorticoids inhibit the induction of nitric oxide synthase in)Tj
T*
(macrophages. Biochem Biophys Res Commun 1990;172:1246-52.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Perkins DJ, St. Clair EW)91.7 (, Misukonis MA, )17.7 (W)79.9 (einber)17.7 (g JB. Reduction)]TJ
2.175 -1.25 Td
(of NOS2 overexpression in rheumatoid arthritis patients treated)Tj
T*
(with anti-tumor necrosis factor alpha monoclonal antibody \(cA2\).)Tj
T*
(Arthritis Rheum 1998;41:2205-10.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Meininger CJ, Kelly KA, Li H, Haynes )17.7 (TE, )17.7 (W)39.8 (u G. Glucosamine)]TJ
2.175 -1.25 Td
(inhibits inducible nitric oxide synthesis. Biochem Biophys Res)Tj
0 Tc T*
(Commun 2000;279:234-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Beckman JS, Beckman )17.7 (TW)91.7 (, Chen J, Marshall P)91.7 (A, Freeman BA.)]TJ
2.175 -1.25 Td
(Apparent hydroxyl radical production by peroxynitrite: implications)Tj
T*
(for endothelial injury from nitric oxide and superoxide. Proc Natl)Tj
0 Tc T*
[(Acad Sci USA)-220.1 (1990;87:1620-4.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative)]TJ
2.175 -1.25 Td
(damage in chronic inflammation. Nitrotyrosine in serum and)Tj
T*
(synovial fluid from rheumatoid patients. FEBS Letts 1994;)Tj
0 Tc 0 Tw T*
(350:9-12.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Halliwell B, Zhao K, )17.7 (Whiteman M. Nitric oxide and peroxynitrite.)]TJ
2.175 -1.25 Td
[(The ugly)64.9 (, the uglier and the not so good: a personal view of recent)]TJ
T*
(controversies. Free Radic Res 1999;31:651-69.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Mapp PI, Klocke R, )17.7 (W)79.9 (alsh DA, et al. Localization of )]TJ
2.175 -1.25 Td
[(3-nitrotyrosine to rheumatoid and normal synovium. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44:1534-39.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Hughes FJ, Buttery LD, Hukkanen M, O\325Donnell )54.8 (A, Maclouf J,)]TJ
2.175 -1.25 Td
(Polak JM. Cytokine-induced prostaglandin E2 synthesis and)Tj
T*
(cyclooxygenase-2 activity are regulated both by a nitric )Tj
T*
(oxide-dependent and -independent mechanism in rat osteoblasts in)Tj
T*
(vitro. J Biol Chem 1999;274:1776-82.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Honda S, Migita K, Hirai )36.8 (Y)128.9 (, et al. Induction of COX-2 expression)]TJ
2.175 -1.25 Td
(by nitric oxide in rheumatoid synovial cells. Biochem Biophys Res)Tj
0 Tc T*
(Commun 2000;268:928-31.)Tj
-0.00011 Tc 30.825 76.25 Td
[(24.)-875.1 (Nathan C, Xie QW)91.7 (. Regulation of biosynthesis of nitric oxide. J)]TJ
0 Tc 2.175 -1.25 Td
(Biol Chem 1994;269:13725-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875.1 (Xie L, Smith JA, Gross SS. GTP)-238.2 (cyclohydrolase I inhibition by the)]TJ
2.175 -1.25 Td
(prototypic inhibitor 2,4-diamino-6-hydroxypyrimidine. J Biol Chem)Tj
0 Tc 0 Tw T*
(1998;273:21091-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Hattori )36.8 (Y)128.9 (, Campbell EB, Gross SS. )54.8 (Ar)17.7 (gininosuccinate synthetase)]TJ
2.175 -1.25 Td
[(mRNA)-220.2 (and activity are induced by immunostimulants in vascular)]TJ
T*
[(smooth muscle. Role in the regeneration or ar)17.7 (ginine for nitric oxide)]TJ
T*
(synthesis. J Biol Chem 1994;269:9405-8.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Nussler )54.8 (AK, Billiar )17.7 (TR, Liu ZZ, Morris SM Jr)54.8 (. Coinduction of)]TJ
2.175 -1.25 Td
[(nitric oxide synthase and ar)17.7 (gininosuccinate synthetase in a murine)]TJ
T*
(macrophage cell line. Implications for regulation of nitric oxide)Tj
T*
(production. J Biol Chem 1994;269:1257-61.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Hattori )36.8 (Y)128.9 (, Gross SS. GTP)-238.2 (cyclohydrolase I mRNA)-220.2 (is induced by)]TJ
2.175 -1.25 Td
(LPS in vascular smooth muscle: characterization, sequence and)Tj
T*
(relationship to nitric oxide synthase. Biochem Biophys Res)Tj
0 Tc T*
(Commun 1993;195:435-41.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (Kef)17.7 (fer J, Probert L, Cazlaris H, et al. )17.7 (T)35 (ransgenic mice expressing)]TJ
2.175 -1.25 Td
(human tumor necrosis factor: a predictive genetic model of)Tj
T*
(arthritis. EMBO J 1991;10:4025-31.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Douni E, )54.8 (Akassoglou K, )54.8 (Alexopoulou L, et al. )17.7 (T)35 (ransgenic and)]TJ
2.175 -1.25 Td
[(knockout analyses of the role of )17.7 (TNF in immune regulation and)]TJ
T*
(disease pathogenesis. J Inflamm 1995-96;47:27-38.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Xie L, Gross SS. )54.8 (Ar)17.7 (gininosuccinate synthetase overexpression in)]TJ
2.175 -1.25 Td
(vascular smooth muscle cells potentiates immunostimulant-induced)Tj
0 Tc T*
(NO production. J Biol Chem 1997;272:16624-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(32.)-875.1 (Hwang O, Baker H, Gross S, Joh )17.7 (TH. Localization of GTP)]TJ
2.175 -1.25 Td
[(cyclohydrolase in monoaminer)17.7 (gic but not nitric oxide-producing)]TJ
T*
(cells. Synapse 1998;28:140-53.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Haddad IY)128.8 (, Pataki G, Hu P)110.7 (, Galliani C, Beckman JS, Matalon S.)]TJ
2.175 -1.25 Td
(Quantitation of nitrotyrosine levels in lung sections of patients and)Tj
T*
[(animals with acute lung injury)64.8 (. J Clin Invest 1994;94:2407-13.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of)]TJ
2.175 -1.25 Td
[(tumor necrosis factor and receptors in models of multior)17.7 (gan failure,)]TJ
T*
(rheumatoid arthritis, multiple sclerosis and inflammatory bowel)Tj
T*
(disease. Immunol Rev 1999;169:175-94.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (V)110.8 (an den Ber)17.7 (g )17.7 (WB, Joosten LA, Kollias G, van de Loo F)73.9 (A. Role of)]TJ
2.175 -1.25 Td
(tumor necrosis factor )Tj
/T1_1 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 9.7265 0 Td
(in experimental arthritis: separate activity)Tj
-9.7265 -1.25 Td
[(of interleukin 1\247 in chronicity and cartilage destruction. )54.8 (Ann)]TJ
T*
(Rheum Dis 1999;58 Suppl I:140-8.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Landino LM, Crews BC, )17.7 (T)35 (immons MD, Morrow JD, Marnett LJ.)]TJ
2.175 -1.25 Td
(Peroxynitrite, the coupling product of nitric oxide and superoxide,)Tj
T*
[(activates prostaglandin biosynthesis. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1996;93:15069-74.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875.1 (Xie L, Hattori )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)35 (ume N, Gross SS. )17.7 (The preferred source of )]TJ
2.175 -1.25 Td
[(ar)17.7 (ginine for high-output nitric oxide synthesis in blood vessels.)]TJ
T*
(Semin Perinatol 2000;24:42-5.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (Gutlich M, Ziegler I, )17.7 (W)39.8 (itter K, et al. Molecular characterization of)]TJ
2.175 -1.25 Td
[(HPH-1: a mouse mutant deficient in GTP)-238.2 (cyclohydrolase I activity)64.8 (.)]TJ
0 Tc T*
(Biochem Biophys Res Commun 1994;203:1675-81.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(39.)-875.1 (Cosentino F)79.7 (, Barker JE, Brand MP)110.7 (, et al. Reactive oxygen species)]TJ
2.175 -1.25 Td
(mediate endothelium-dependent relaxations in )Tj
0.00729 Tw T*
[(tetrahydrobiopterin-deficient )-17.7 (mice. )37.1 (Arterioscler Thromb V)110.8 (asc )-17.7 (Biol)]TJ
0 Tc 0 Tw T*
(2001;21:496-502.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (Altindag ZZ, Sahin G, Inanici F)79.7 (, Hascelik Z. Urinary neopterin)]TJ
2.175 -1.25 Td
(excretion and dihydropteridine reductase activity in rheumatoid)Tj
T*
[(arthritis. Rheumatol Int 1998;18:107-1)36.8 (1.)]TJ
ET
0 0 0 0 scn
429 777 128 -27 re
f*
428 770 130 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Hukkanen, et al: NO pathway in transgenic mice)Tj
0 Tc 0 Tw 61.4375 -0.0313 Td
(659)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
80 0 obj
<>
endobj
90 0 obj
<>
endobj
71 0 obj
<>
endobj
111 0 obj
<>
endobj
133 0 obj
<>
endobj
68 0 obj
<>
endobj
104 0 obj
<>stream
H{PSWrCPH[;*">@SQUDTR!H$!">Vu;Rvm32㣿ݨNΙΙ~s98fo8v[懋$B
X>agoi=d7߉d8@Ww gaĵsHgW68o:iJ&JLRП^"pقAWA 8!S%W%rzsrT" _rZ&e"9-2AP"QTJAiAr"iqrQH cma86d&ֲgLaR|°/m6` 6Ɲq
oig'3lפ/i`e8D;c82J3S驒O>wj24ǏY坫;7J(}F̀Y\Gn
'=/jR)z$'b
0|*JRf9ے~AtfP'`~z#=ׯ+5ז&-55@XlF&LV]uOٜb7?`<(C=&$Jk,e5c5zq~Q!ѓ:rWVP
NbO=T)9f̢ԬPnYCcŅG'/O+|8ldW.*4T]xPwvPԴ]tvdBj`8Q@I/a^S=M
6$BMP|#/PK H[(+>*Ea7(
4ܲ9aM_5_DN`Օ*S>KjH/+bVp1L0Ԥd VP
m .ne !QdXp^Msw&K
֧(ޅ
iRQrT+HȬ